What is the present world scenario of intellectual property rights with respect to life materials? Although, India is second in the world to file patents, still only a few have been commercialized. Explain the reasons behind this less commercialization.

Introduction

Intellectual Property Rights (IPRs) related to life materials—such as genetic resources, biotechnological innovations, and pharmaceuticals—are a contentious global issue. While developed nations dominate patent filings in biotechnology, developing countries like India are emerging as significant contributors. India ranks second globally in patent filings (WIPO, 2022), yet the commercialization rate of these patents remains low, highlighting a critical gap in translating innovation into marketable products.

Value Addition Block — Key Global Trends in IPRs for Life Materials

Global Scenario of IPRs in Life Materials

• Developed Nations' Dominance: Countries like the USA, EU, and Japan lead in patent filings for life materials, leveraging advanced R&D ecosystems and strong legal frameworks.
• Emerging Economies' Contribution: Nations like India and China are rapidly increasing their share in patent filings, driven by government initiatives and growing biotech industries.
• Ethical and Legal Challenges: Issues like biopiracy, access to genetic resources, and benefit-sharing under the Nagoya Protocol remain unresolved.
• TRIPS Agreement: While it harmonizes global IPR standards, it often creates barriers for developing nations in accessing patented life-saving technologies.

Reasons for Low Commercialization of Patents in India

1. Weak Industry-Academia Linkages

• Reason: Limited collaboration between research institutions and industries hinders the translation of patents into market-ready products.
• Example: Despite significant research output from premier institutes like CSIR and IITs, few patents are licensed to industries.

2. Lack of Funding for Commercialization

• Reason: High costs of scaling up innovations, coupled with inadequate venture capital and government support, deter commercialization.
• Example: Biotech startups in India often struggle to secure funding for clinical trials or product development.

3. Inadequate Infrastructure

• Reason: Absence of advanced testing facilities, incubation centers, and manufacturing units delays the commercialization process.
• Example: India lags in establishing biotech parks compared to countries like China.

4. Regulatory Hurdles

• Reason: Lengthy and complex approval processes for life material-based products, such as drugs and GMOs, discourage commercialization.
• Example: The Genetic Engineering Appraisal Committee (GEAC) often faces criticism for delays in approving GM crops.

5. Low Market Orientation of Patents

• Reason: Many patents filed in India are incremental innovations or lack market relevance, reducing their commercial viability.
• Example: A significant proportion of patents filed are never pursued beyond the filing stage.

6. Global Competition and Licensing Issues

• Reason: Indian innovators face stiff competition from global players and often lack expertise in negotiating licensing agreements.
• Example: Indian firms struggle to compete with multinational corporations in the pharmaceutical sector.

7. Awareness and Skill Gaps

• Reason: Limited awareness among researchers about patent commercialization and lack of skilled IPR professionals.
• Example: Many researchers focus on patent filing as an academic achievement rather than a commercial opportunity.

Way Forward

• Strengthening Industry-Academia Collaboration: Establishing technology transfer offices and incentivizing partnerships between research institutions and industries.
• Enhancing Funding Mechanisms: Expanding government schemes like Biotechnology Ignition Grant (BIG) and promoting venture capital investments.
• Streamlining Regulatory Processes: Simplifying approval mechanisms for life material-based products to reduce delays.
• Building Infrastructure: Developing biotech parks, incubation centers, and advanced testing facilities.
• Capacity Building: Training researchers and entrepreneurs in patent commercialization and licensing strategies.
• Global Partnerships: Leveraging international collaborations for technology transfer and market access.

Conclusion

India's position as the second-largest patent filer globally reflects its growing innovation potential. However, addressing challenges like weak industry linkages, funding gaps, and regulatory hurdles is essential to enhance commercialization rates. By fostering a robust ecosystem for innovation and commercialization, India can emerge as a global leader in life material-based technologies, contributing to both economic growth and societal well-being.